

RECEIVED  
CENTRAL FAX CENTER

APR 04 2005

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
666 FIFTH AVENUE, 31ST FLOOR  
NEW YORK, NEW YORK 10103-3198  
WWW.FULBRIGHT.COM

**FACSIMILE TRANSMISSION**

**DATE:** April 4, 2005

**MATTER NUMBER:** -01030 10109097

<b>RECIPIENT(S):</b>	<b>FAX NO.:</b>	<b>PHONE NO.:</b>
<b>Examiner Fozia M. Hamud Art Unit 1647 Commissioner for Patents</b>	<b>1571-273-0884 and 1703-872-9306</b>	<b>1571-272-0884</b>

**FROM:** Norman Hanson

**FLOOR: 24**

**PHONE:** (212) 318-3168

**FAX:** (212) 318-3400

**U.S. Serial No. 10/026,106**

RE: LUD 5752

NUMBER OF PAGES INCLUDING COVER PAGE: 9

**Message:**

**CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL  
FANI MALIKOUZAKIS AT 212 3183220 AS SOON AS POSSIBLE.**

APR 04 2005

LUD 5752 (10109097)

**CERTIFICATE OF FACSIMILE TRANSMITTAL**

I hereby certify that this correspondence is being transmitted via FACSIMILE pursuant to 37 CFR 1.8 to **Group 1647, Examiner Fozia M. HAMUD** of the Commissioner for Patent at (571) 273-0884 and (703) 872-9306 on April 4, 2005.

Fani Malikouzakis  
(Name of Transmitter)

*Fani Malikouzakis*  
(Signature)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Jean-Christophe RENAULD et al.

Group Art Unit: 1647

US Serial No.: 10/026,106

Examiner: Fozia M. HAMUD

Filing Date: December 21, 2001

Confirmation No. 7513

For: ISOLATED CYTOKINE RECEPTOR LICR-2**RESPONSE TO OFFICE ACTION**  
**(37 C.F.R. § 1.111)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is submitted in response to the Office Action of January 10, 2005. No amendments are proffered herewith.

The Examiner has maintained rejections under 35 U.S.C. § 101/112. The Examiner's position has been considered, and reconsideration is requested, for the reasons which follow.

The Examiner asserts that the fact that the molecule at issue, i.e., LICR-2, activates STATs, is not a sufficient utility because "a variety of molecules activate STATs."

Applicants do not dispute this; however, they again call upon the Examiner to supply a statute, case, or regulation that states that, for a compound to exhibit utility under 35 U.S.C. § 101, it must be the only molecule known to have that activity.

LUD 5752 (10109097)

Applicants are entitled to this information. If an Examiner raises a rejection, applicants are entitled to see the support underlying the rejection. If the support cannot be provided, the rejection should be withdrawn.

The Examiner also asserts that "because one of ordinary skill in the art would not know which physiological process is (sic) the protein of the instant invention (sic; is) involved in" there is no proven utility. Again, there is no basis for this novel approach to the utility requirement. The fact that LICR-2 activates a molecule involved in therapeutic processes is a substantial activity. The Examiner's position is not sustainable.


Notwithstanding these filings, applicants would like to bring the Examiner's attention to further utilities, as discussed in the specification. Specifically, LICR-2 is a binding partner for AK155, which is linked to Herpes virus saimiri infection. Please note page 2, lines 15-19, page 7, last paragraph of example 6, page 19, first paragraph, page 20 in toto.

Appended hereto is a copy of Knappe, et al., *J. Virol.*, 74(8): 3881-3887 (2000), discussing the fact that *ak155* is a marker for Herpes virus saimiri infection.

It is submitted that the fact that LICR-2 acts as a binding partner for *ak155* clearly provides utility of the type requested by the Examiner - which is well more than the statute requires.

In view of this, it is believed that the rejection cannot be sustained, and allowance of this application is proper and is urged.

Respectfully submitted,

By   
Norman D. Hanson  
Registration No.: 30,946  
FULBRIGHT & JAWORSKI L.L.P.  
666 Fifth Avenue  
New York, New York 10103  
Attorney for Applicant

212 318-3000  
212 318-3400 (fax)

Attachment: Knappe et al. Reference